# Tevogen Bio Holdings Inc. (TVGN)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $10.60 (-1.40%)

> Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies using its ExacTcell™ platform to harness CD8+ cytotoxic T lymphocytes for treating infectious diseases, cancers, and neurological disorders. The company targets antigens present only on diseased cells to spare healthy tissue, enhancing safety through naturally occurring T cell receptors, with applications spanning oncology, neurology, and virology. Key product candidates include TVGN 489, which has completed Phase 1 trials for high-risk COVID-19 patients and is in Phase 1 for acute SARS-CoV-2 in B-cell suppressed individuals and Long COVID; TVGN 920 and TVGN 960 in preclinical stages for cervical and oropharyngeal cancers; TVGN 601 for multiple sclerosis; TVGN 930 for Epstein-Barr virus-associated lymphomas; and TVGN 116 for hepatitis B. Tevogen Bio Holdings Inc. also advances Tevogen.AI, applying proprietary predictive technologies like PredicTcell™ to accelerate drug development through immunologically active peptide identification. Founded in 2020 and headquartered in Warren, New Jersey, the company focuses on making therapies commercially viable and accessible to broad patient populations in the biotechnology sector.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/TVGN)